The best products are often developed when the product manager is also a customer, or in the case of biotech, when the CEO is also a patient. Hear from Nick Sireau of Serenatis Bio, who developed a product that’s on the market for an ultra-rare disease, and is now preparing for a series A raise for an OCD asset after a successful seed raise. Nick’s story, including how Life Science Nation’s training, data, and events helped him, is an inspiring tale of keeping the patient first while navigating the labyrinth of the investment landscape. When Nick one day received a newsletter from Dennis Ford, CEO of LSN, saying that you need 600 – 800 investor leads to do a successful raise, he re-evaluated his strategy and realized it was a numbers game, and he had to play it fast. He searched LSN’s investor database of thousands of investors to find the best fits in the least amount of time, and participated in training from Greg Mannix, VP of International Business Development of LSN, on how to pitch and optimize partnering strategies. Now he’s on the hopeful path of bringing a treatment to a condition that is absolutely devoid of good treatment options, that can dramatically reduce quality of life and even lead to suicide. If you are an entrepreneur fundraising, this video will give you sage advice that you can use right away to accelerate your raise.

Nick Sireau became a new father in 2000. However, the usual joys of parenthood were quickly cut short when Nick discovered his son had black bone disease, also known as alkaptonuria, a debilitating condition for which there was no treatment. Two years later a second son came into Nick’s life, similarly afflicted. Nick, a solar power entrepreneur, embarked on the journey of a lifetime to find a cure. Raising money any way he knew how, from half marathons to grants from the European Commission, Nick funded and led the research needed to repurpose a drug and get it approved for alkaptonuria. Click here to watch the incredible story of courage, resilience, and a refusal to give up that produced a near-perfect treatment for an ultra-rare disease that diminishes the lives of over 20,000 patients worldwide. Repurposed drugs for ultra-rare diseases rarely see the light of day due to lack of commercial incentive. Heroes like Nick, and rare disease patients everywhere, need policy-based help to provide the incentives for investors and pharmas to move more promising assets forward. At Life Science Nation, we are dedicated to connecting innovators with the capital they need to help patients. Join Nick and other heroes at Life Science Nation’s RESI conferences and become part of the solution.

The two biggest biopharma licensing and investment events, BIO and RESI, respectively, will be in Boston mid-June. BIO will feature thousands of large pharma delegates seeking licensing candidates while RESI will have over 400 seed through series B investors and pharma external innovation scouts. If you’re targeting a pharma deal in the short or long term, you should know which pharmas are best fits for you, and you should be starting conversations with them already. This applies equally if you’re seeking funding or out-licensing. Earlier stage companies will want to court the early innovation scouts at RESI while later stage biotechs will want to target the BD&L scouts at BIO.

To help you determine which pharma partners are optimally aligned with your company and submit your non-confidential deck or proposal in advance of BIO and RESI, we’ve provided the LSN Pharma Directory. This guide lists the business development/licensing/partnering pages for the top pharmas and lets you instantly see their licensing goals. Get the conversation started (for follow-up at BIO and RESI) by leveraging the submission portals contained in the Directory. The hundreds of investors attending BIO will want to see that you have a solid exit plan and have a good sense of the competitive landscape. Check out the LSN Pharma Directory for free now!